Literature DB >> 16005601

A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer.

O Gemer1, M Lurian, M Gdalevich, V Kapustian, E Piura, D Schneider, O Lavie, T Levy, A Fishman, R Dgani, H Levavi, U Beller.   

Abstract

AIMS: To provide a large database of pre-operative CA 125 levels which may predict inappropriate cytoreductive surgery in patients with advanced epithelial ovarian cancer.
METHODS: A multicenter review of the records of 424 patients with FIGO stage III and IV epithelial ovarian cancer of patients who underwent primary cytoreductive surgery was performed. The validity of pre-operative CA 125 level measurement as a single predictor of the possibility to achieve only suboptimal cytoreduction was evaluated by calculating the sensitivity and the specificity of various cut-off values. The relative importance of different cut-off values in achieving the best predictive validity was assessed by a receiver operating characteristics (ROC) curve.
RESULTS: Optimal cytoreduction (largest diameter of residual tumour < or =1 cm) was achieved in 242 patients. The median CA 125 level in optimally cytoreduced patients was lower than in those patients suboptimally debulked (304 vs 863 U/mL; p<0.001). The area under the ROC curve was 0.65 (95% confidence interval, 0.60-0.71) and the CA 125 threshold derived from the ROC was 400 U/mL. The accuracy of the test at this level was 62%.
CONCLUSIONS: The clinical applicability of the ROC derived CA 125 threshold is limited. The data accrued in the study provides a basis for decision-making regarding the place of primary surgery various CA 125 levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005601     DOI: 10.1016/j.ejso.2005.05.009

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  8 in total

Review 1.  Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls.

Authors:  Iván Díaz-Padilla; Albiruni Ryan Abdul Razak; Lucas Minig; Marcus Q Bernardini; Josep María Del Campo
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

Review 2.  A framework for a personalized surgical approach to ovarian cancer.

Authors:  Alpa M Nick; Robert L Coleman; Pedro T Ramirez; Anil K Sood
Journal:  Nat Rev Clin Oncol       Date:  2015-02-24       Impact factor: 66.675

3.  A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.

Authors:  Mona Aarenstrup Karlsen; Carsten Fagö-Olsen; Estrid Høgdall; Tine Henrichsen Schnack; Ib Jarle Christensen; Lotte Nedergaard; Lene Lundvall; Magnus Christian Lydolph; Svend Aage Engelholm; Claus Høgdall
Journal:  Tumour Biol       Date:  2016-07-20

Review 4.  Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer.

Authors:  Peter E Schwartz
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

5.  A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

Authors:  Rudy S Suidan; Pedro T Ramirez; Debra M Sarasohn; Jerrold B Teitcher; Svetlana Mironov; Revathy B Iyer; Qin Zhou; Alexia Iasonos; Harold Paul; Masayoshi Hosaka; Carol A Aghajanian; Mario M Leitao; Ginger J Gardner; Nadeem R Abu-Rustum; Yukio Sonoda; Douglas A Levine; Hedvig Hricak; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2014-07-11       Impact factor: 5.482

Review 6.  The Significance of Normal Pretreatment Levels of CA125 (<35 U/mL) in Epithelial Ovarian Carcinoma.

Authors:  Joseph Menczer; Erez Ben-Shem; Abraham Golan; Tally Levy
Journal:  Rambam Maimonides Med J       Date:  2015-01-29

7.  Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.

Authors:  Li-Yuan Feng; Sheng-Bin Liao; Li Li
Journal:  J Ovarian Res       Date:  2020-02-12       Impact factor: 4.234

8.  Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study.

Authors:  Mengdi Fu; Chengjuan Jin; Shuai Feng; Zongyang Jia; Lekai Nie; Yang Zhang; Jin Peng; Xia Wang; Hualei Bu; Beihua Kong
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.